Glimepiride/Rosiglitazone Side Effects

Please note - some side effects for Glimepiride/Rosiglitazone may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.

Side Effects of Glimepiride/Rosiglitazone - for the Consumer

Glimepiride/Rosiglitazone

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome when using Glimepiride/Rosiglitazone:

Cold-like symptoms; headache.

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue; unusual hoarseness); blurred vision or other vision changes; chest, jaw, or arm pain or discomfort; confusion; fainting; fever, chills, or persistent sore throat; increased or painful urination; lightheadedness; menstrual changes; numbness of an arm or a leg; red, swollen, blistered, or peeling skin; sudden, severe headache, vomiting, or dizziness; symptoms of heart failure (eg, shortness of breath; sudden, unexplained weight gain; swelling of the hands, ankles, legs, or feet); symptoms of liver problems (eg, dark urine, severe or persistent nausea, stomach pain, unexplained vomiting or loss of appetite, yellowing of the skin or eyes); symptoms of low blood sugar (eg, anxiety, chills, dizziness or drowsiness, fast heartbeat, headache, increased hunger, increased sweating, tremors); unusual bone pain (especially in the hand, foot, or upper arm); unusual bruising or bleeding; unusual tiredness or weakness.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.

Side Effects by Body System - for Healthcare Professionals

Endocrine

Endocrine side effects have included hypoglycemia.

Cardiovascular

Cardiovascular side effects have included edema and congestive heart failure.

Respiratory

Respiratory side effects have included upper respiratory tract infection, pulmonary edema and pleural effusions.

Nervous system

Nervous system side effects have included dizziness, asthenia, and headache.

General

General side effects have included injury.

Gastrointestinal

Gastrointestinal side effects have included nausea, vomiting, gastrointestinal pain, and diarrhea,

Hepatic

Hepatic side effects have included elevations of liver enzyme levels, cholestasis, jaundice, and hepatitis.

Hypersensitivity

Hypersensitivity side effects have included angioedema and urticaria.

Dermatologic

Dermatologic side effects have included pruritus, erythema, urticaria, porphyria cutanea tarda, photosensitivity reactions, allergic vasculitis, and morbilliform or maculopapular eruptions.

Hematologic

Hematologic side effects have included leukopenia, agranulocytosis, thrombocytopenia, hemolytic anemia, aplastic anemia, and pancytopenia.

Metabolic

Metabolic side effects have included hepatic porphyria reactions, disulfiram-like reactions, and hyponatremia. The syndrome of inappropriate antidiuretic hormone (SIADH) secretion has been reported.

Ocular

Ocular side effects have included changes in accommodation and blurred vision. New onset or worsening (diabetic) macular edema with decreased visual acuity has been reported very rarely in postmarketing experience with rosiglitazone. In some cases, symptoms improved following discontinuation of rosiglitazone. Physicians should consider the possibility of macular edema if a patient reports decreased visual acuity.

Musculoskeletal

Musculoskeletal side effects have included an increased incidence of bone fracture in female patients. The majority of the fractures in the women who received rosiglitazone occurred in the upper arm, hand, and foot. These sites of fracture are different from those usually associated with postmenopausal osteoporosis (e.g., hip or spine). No increase in fracture rates was observed in men treated with rosiglitazone.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.